-+ 0.00%
-+ 0.00%
-+ 0.00%

Keros Therapeutics Swings to Q3 Net Income of $14.15 Million

PUBT·11/05/2026 21:03:19
Listen to the news
Keros Therapeutics Swings to Q3 Net Income of $14.15 Million
  • Keros Therapeutics swung to third-quarter 2026 net income of $14.15 million, primarily due to revenue recognized under its Takeda license agreement.
  • Revenue more than doubled year over year to $40.01 million.
  • September 30 cash and cash equivalents totaled $259.46 million, with funding expected to last into the second half of 2028.
  • The Phase 2 rinvatercept DMD trial dosed its first patient in September 2026; initial data are expected in the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051601PRIMZONEFULLFEED9870629) on November 05, 2026, and is solely responsible for the information contained therein.